Fundraisings and IPOs

Date: 2018-10-10

Type of information: Grant

Company: Secarna Pharmaceuticals (Germany)

Investors: European Commission’s Horizon 2020 programme


Funding type: grant

Planned used:

  • Secarna Pharmaceuticals is a next generation antisense oligonucleotide (ASO) company with antisense therapies in various stages of pre-clinical development in the areas of immunooncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications.  The company is a partner in the INAT consortium (Inhaled Nanocarriers with Antisense Therapy for lung fibrosis) which aims to develop a novel nanomedicine for the treatment of Idiopathic Pulmonary Fibrosis (IPF). In the INAT project, the novel nanomedicine is administered locally and non-invasively via aerosols into the lungs and inhibits a newly discovered gene associated with the disease. The drug candidates could also be effective for fibrotic diseases of other organs such as liver or kidney.


  • • On October 10, 2018, Secarna Pharmaceuticals, a new breed biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets in a number of organ systems, announced that the company will receive an EU grant under the ERA-Net Co-fund scheme of the Horizon 2020 Research and Innovation Framework Programme for multidisciplinary and translational research and innovation projects (EuroNanoMed III). The duration of the grant is expected to be three years. The grant will fund the INAT project (Inhaled Nanocarriers with Antisense Therapy for lung fibrosis).
  • The INAT consortium (INSERM, Université F. Rabelais de Tours, France, German Research Center for Environmental Health GmbH, Germany, Université catholique de Louvain, Belgium and DIV’INCELL, France) synergistically combines the efforts of three academic labs with complimentary expertise in aerosol medicine and two platform technology partners.
  • The innovative, biodegradable and highly effective nanoparticle carrier of one partner combined with an oligonucleotide produced by Secarna Pharmaceuticals will target a specific profibrosis mediator. The resulting nanomedicine will ultimately be formulated for inhalation in humans and its toxicity and efficacy tested preclinically by three out of the five consortium members.

Therapeutic area: Rare diseases - Fibrotic diseases - Lung diseases

Is general: Yes